{"text_format":"5","workbook":"xls","n_sheets":1,"sheets":["report2"],"props":{"last_modified_by":"sharecat"},"not_rendered":{"external_links":1,"defined_names":1},"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":25,"n_cols":5,"rows_kept":25,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[3,2,3,3],[7,2,7,3],[8,2,8,3],[10,2,10,3],[12,2,12,3],[13,2,13,3],[17,2,17,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910826980703321"]
[null,null,"Titolo",null,"Novel therapeutic targets for anti-arrhythmic drugs [[electronic resource] /] / edited by George E. Billman"]
[null,null,"Pubbl/distr/stampa",null,"Hoboken, NJ, : John Wiley & Sons, c2010"]
[null,null,"ISBN",null,"1-282-68839-1"]
[{"$nulls":4},"9786612688393"]
[{"$nulls":4},"0-470-56141-6"]
[{"$nulls":4},"0-470-56140-8"]
[null,null,"Descrizione fisica",null,"1 online resource (612 p.)"]
[null,null,"Disciplina",null,"615.716"]
[{"$nulls":4},"616.128061"]
[null,null,"Soggetti",null,"Myocardial depressants"]
[{"$nulls":4},"Arrhythmia - Chemotherapy"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[{"$nulls":3},"Livello bibliografico","Monografia"]
[{"$nulls":3},"Note generali","Description based upon print version of record."]
[{"$nulls":3},"Nota di bibliografia","Includes bibliographical references and index."]
[null,null,"Nota di contenuto",null,"NOVEL THERAPEUTIC TARGETS FOR ANTIARRHYTHMIC DRUGS; CONTENTS; Acknowledgments; Contributors; 1. Introduction; References; 2. Myocardial K(+) Channels: Primary Determinants of Action Potential Repolarization; 2.1 Introduction; 2.2 Action Potential Waveforms and Repolarizing K(+) Currents; 2.3 Functional Diversity of Repolarizing Myocardial K(+) Channels; 2.4 Molecular Diversity of K(+) Channel Subunits; 2.5 Molecular Determinants of Functional Cardiac I(to) Channels; 2.6 Molecular Determinants of Functional Cardiac I(K) Channels; 2.7 Molecular Determinants of Functional Cardiac Kir Channels"]
[{"$nulls":4},"2.8 Other Potassium Currents Contributing to Action Potential Repolarization2.8.1 Myocardial K(+) Channel Functioning in Macromolecular Protein Complexes; References; 3. The \"Funny\" Pacemaker Current; 3.1 Introduction: The Mechanism of Cardiac Pacemaking; 3.2 The \"Funny\" Current; 3.2.1 Historical Background; 3.2.2 Biophysical Properties of the I(f) Current; 3.2.3 Autonomic Modulation; 3.2.4 Cardiac Distribution of I(f); 3.3 Molecular Determinants of the I(f) Current; 3.3.1 HCN Clones and Pacemaker Channels; 3.3.2 Identification of Structural Elements Involved in Channel Gating"]
[{"$nulls":4},"3.3.3 Regulation of Pacemaker Channel Activity: \"Context\" Dependence "]
[{"$nulls":4},"and Protein-Protein Interactions3.3.4 HCN Gene Regulation; 3.4 Blockers of Funny Channels; 3.4.1 Alinidine (ST567); 3.4.2 Falipamil (AQ-A39), Zatebradine (UL-FS 49), and Cilobradine (DK-AH269); 3.4.3 ZD7288; 3.4.4 Ivabradine (S16257); 3.4.5 Effects of the Heart Rate Reducing Agents on HCN Isoforms; 3.5 Genetics of HCN Channels; 3.5.1 HCN-KO Models; 3.5.2 Pathologies Associated with HCN Dysfunctions; 3.6 HCN-Based Biological Pacemakers; References; 4. Arrhythmia Mechanisms in Ischemia and Infarction; 4.1 Introduction"]
[{"$nulls":4},"4.1.1 Modes of Ischemia, Phases of Arrhythmogenesis4.1.2 Trigger-Substrate-Modulating Factors; 4.2 Arrhythmogenesis in Acute Myocardial Ischemia; 4.2.1 Phase 1A; 4.2.2 Phase 1B; 4.2.3 Arrhythmogenic Mechanism: Trigger; 4.2.4 Catecholamines; 4.3 Arrhythmogenesis During the First Week Post MI; 4.3.1 Mechanisms; 4.3.2 The Subendocardial Purkinje Cell as a Trigger 24-48 H Post Occlusion; 4.3.3 Five Days Post-Occlusion: Epicardial Border Zone; 4.4 Arrhythmia Mechanisms in Chronic Infarction; 4.4.1 Reentry and Focal Mechanisms; 4.4.2 Heterogeneity of Ion Channel Expression in the Healthy Heart"]
[{"$nulls":4},"4.4.3 Remodeling in Chronic Myocardial Infarction4.4.4 Structural Remodeling; 4.4.5 Role of the Purkinje System; References; 5. Antiarrhythmic Drug Classification; 5.1 Introduction; 5.2 Sodium Channel Blockers; 5.2.1 Mixed Sodium Channel Blockers (Vaughan Williams Class Ia); 5.3 Inhibitors of the Fast Sodium Current with Rapid Kinetics (Vaughan Williams Class Ib); 5.3.1 Lidocaine; 5.3.2 Mexiletine; 5.4 Inhibitors of the Fast Sodium Current with Slow Kinetics (Vaughan Williams Class Ic); 5.4.1 Flecainide; 5.4.2 Propafenone"]
[{"$nulls":4},"5.5 Inhibitors of Repolarizing K(+) Currents (Vaughan Williams Class III)"]
[{"$nulls":3},"Sommario/riassunto","Profiles potential treatment approaches for cardiac arrhythmias Cardiac arrhythmias of ventricular origin are responsible for the deaths of nearly half a million Americans each year while atrial fibrillation accounts for about 2.3 million cases per year, a rate that is projected to increase 2.5 fold over the next half century. Effectively managing these cardiac rhythm disorders remains a major challenge for both caregivers and the pharmaceutical industry. Filling a gap in the current literature, Novel Therapeutic Targets for Antiarrhythmic Drugs presents the latest treatments f"]